OptimizeRx Corp Quarterly Weighted Average Number of Shares Outstanding, Diluted from Q3 2015 to Q3 2024

Taxonomy & unit
us-gaap: shares
Description
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
Summary
OptimizeRx Corp quarterly/annual Weighted Average Number of Shares Outstanding, Diluted history and growth rate from Q3 2015 to Q3 2024.
  • OptimizeRx Corp Weighted Average Number of Shares Outstanding, Diluted for the quarter ending September 30, 2024 was 18.3M shares, a 10.1% increase year-over-year.
  • OptimizeRx Corp annual Weighted Average Number of Shares Outstanding, Diluted for 2023 was 17.1M shares, a 3.71% decline from 2022.
  • OptimizeRx Corp annual Weighted Average Number of Shares Outstanding, Diluted for 2022 was 17.8M shares, a 0.53% increase from 2021.
  • OptimizeRx Corp annual Weighted Average Number of Shares Outstanding, Diluted for 2021 was 17.7M shares, a 19.3% increase from 2020.
Weighted Average Number of Shares Outstanding, Diluted, Quarterly (shares)
Weighted Average Number of Shares Outstanding, Diluted, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2024 18.3M +1.69M +10.1% Jul 1, 2024 Sep 30, 2024 10-Q 2024-11-14
Q2 2024 18.3M +1.27M +7.45% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-15
Q1 2024 18.2M +1.08M +6.29% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-15
Q4 2023 17.1M -659K -3.71% Oct 1, 2023 Dec 31, 2023 10-K 2024-04-15
Q3 2023 16.6M -1.34M -7.47% Jul 1, 2023 Sep 30, 2023 10-Q 2024-11-14
Q2 2023 17M -1.13M -6.24% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-15
Q1 2023 17.1M -783K -4.38% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-15
Q4 2022 17.8M +93.5K +0.53% Oct 1, 2022 Dec 31, 2022 10-K 2024-04-15
Q3 2022 18M -217K -1.19% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 18.1M +17.7K +0.1% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-14
Q1 2022 17.9M +1.78M +11% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-12
Q4 2021 17.7M +2.86M +19.3% Oct 1, 2021 Dec 31, 2021 10-K 2023-03-10
Q3 2021 18.2M +3.3M +22.1% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-08
Q2 2021 18.1M +3.44M +23.4% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 16.1M +1.49M +10.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 14.8M +1.44M +10.8% Oct 1, 2020 Dec 31, 2020 10-K/A 2023-03-10
Q3 2020 14.9M +754K +5.33% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 14.7M +860K +6.23% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-04
Q1 2020 14.6M +1.53M +11.7% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q4 2019 13.4M +1.52M +12.9% Oct 1, 2019 Dec 31, 2019 10-K 2021-03-08
Q3 2019 14.1M +1.22M +9.48% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 13.8M +1.86M +15.5% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-05
Q1 2019 13.1M +3.29M +33.6% Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-06
Q4 2018 11.9M Oct 1, 2018 Dec 31, 2018 10-K 2020-03-26
Q3 2018 12.9M +3.17M +32.5% Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-05
Q2 2018 11.9M +2.09M +21.2% Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-07
Q1 2018 9.79M Jan 1, 2018 Mar 31, 2018 10-Q 2019-05-08
Q3 2017 9.75M Jul 1, 2017 Sep 30, 2017 10-Q 2018-11-05
Q2 2017 9.86M Apr 1, 2017 Jun 30, 2017 10-Q 2018-08-07
Q3 2015 24.3M Jul 1, 2015 Sep 30, 2015 10-Q 2016-11-07
* An asterisk sign (*) next to the value indicates that the value is likely invalid.